ClinicalTrials.gg
CompletedNCT05117554ARC-14Updated Oct 17, 2024

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

A Phase 1 interventional study of casdatifan and Placebo in Healthy Participants, sponsored by Arcus Biosciences, Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Arcus Biosciences, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • AB521
  • HIF-2α
  • hypoxia-inducible factor 2 alpha
  • Single ascending dose (SAD)
  • Multiple ascending dose (MAD)
  • Drug-drug interaction (DDI)
  • casdatifan
03

In context

Lead sponsor

Arcus Biosciences, Inc. is the lead sponsor of 32 studies on the registry; 4 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy volunteers (in the opinion of the investigator) as determined by pre-study medical history, physical examination, vital signs, and 12-lead (ECG)
  • All clinical laboratory tests of blood and urine must be within the normal range or show no excursions from the normal range as judged by Principal Investigator at screening and admission.
  • Screening and randomization ≥for males and females is as follows:

    • SAD: male and female hemoglobin level ≥ 12.5 grams/ deciliters (g/dL) (7.7 millimoles/liters [mmol/L])
    • MAD and DDI: male hemoglobin level ≥ 14.2 g/dL (8.8 mmol/L) and female hemoglobin level ≥ 12.5 g/dL (7.7 mmol/L).
  • Participants should have adequate peripheral venous access.
  • Body weight of 45 kilograms (kg) or greater and within the range of 18 to 32 kg/meters squared (m\^2) (inclusive)
  • Male participants must be vasectomized and have been vasectomized for at least 3 months prior to screening visit with confirmed history of azoospermia subsequent to the vasectomy procedure
  • use should be consistent with local regulations

Exclusion criteria

Exclusion Criteria:

  • Has any (acute or chronic [including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection]) medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
  • Has history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, cerebrovascular, neurological, or other major disorders capable of significantly altering the absorption, metabolism, or elimination of drug; constituting a risk when taking the study intervention; or interfering with the interpretation of data in the opinion of the investigator
  • Abnormal blood pressure (BP) or pulse measurements at the Screening Visit or Day -2/-1 (Admission) in a supine position after 5 minutes of rest as follows: mean systolic BP ≥139 millimeters of mercury (mm Hg) or mean diastolic BP ≥89 mm Hg; mean pulse \< 40 beats per minute (bpm) or > 100 bpm.
  • Liver enzyme test results: , aspartate aminotransferase, , or alkaline phosphatase >1.0x the
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities
  • Has 12-lead with changes considered to be at the Screening Visit or day of admission
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    SAD-casdatifan Dose 1

    Participants will receive "Dose 1" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Experimental
    SAD-casdatifan Dose 2

    Participants will receive "Dose 2" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Experimental
    SAD-casdatifan Dose 3

    Participants will receive "Dose 3" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Experimental
    SAD-casdatifan Dose 4

    Participants will receive "Dose 4" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Placebo comparator
    SAD-Placebo

    Participants will receive matching placebo orally with water under fasting conditions.

    Drug: Placebo

  • Experimental
    MAD-casdatifan Dose 1

    Participants will receive "Dose 1" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Experimental
    MAD-casdatifan Dose 2

    Participants will receive "Dose 2" of casdatifan orally with water under fasting conditions.

    Drug: casdatifan

  • Placebo comparator
    MAD-Placebo

    Participants will receive matching placebo orally with water under fasting conditions.

    Drug: Placebo

  • Experimental
    DDI-casdatifan Dose + Midazolam

    Participants will receive highest safe dose level of casdatifan from MAD and midazolam orally with water under fasting conditions

    Drug: casdatifan · Drug: Midazolam

Interventions

  • Capsule

    Also known as: AB521

  • DrugPlacebo

    Capsule

  • DrugMidazolam

    Syrup solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 21.5 Weeks

  2. Number of Participants With Abnormal Changes From Baseline in Laboratory Parameter Values

    Time frame: Baseline; Up to 21.5 Weeks

  3. Number of Participants With Abnormal Changes from Baseline in Vital Sign Values

    Time frame: Baseline; Up to 21.5 Weeks

  4. Maximum Observed Plasma Concentration (Cmax) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  5. Area Under the Plasma Concentration Time Curve From Hour 0 to the Last Sample With Measurable Plasma Concentrations (AUClast) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  6. Time of Occurrence of Cmax (tmax) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  7. Apparent Terminal Elimination Rate Constant (λz) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  8. Terminal Half-Life (t1/2) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  9. Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUCinf) of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  10. Apparent Volume of Distribution of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  11. Apparent Total Body Clearance of casdatifan

    Time frame: multiple timepoints up to approximately 21.5 Weeks

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  2. Area Under the Plasma Concentration Time Curve From Hour 0 to the Last Sample With Measurable Plasma Concentrations (AUClast) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  3. Time of Occurrence of Cmax (tmax) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  4. Apparent Terminal Elimination Rate Constant (λz) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  5. Terminal Half-Life (t1/2) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  6. Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUCinf) of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  7. Apparent Volume of Distribution of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

  8. Apparent Total Body Clearance of midazolam and 1 hydroxymidazolam

    Time frame: multiple timepoints up to approximately 21.5 Weeks

07

Study locations

1 site
  • Investigational Site
    Groningen, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Nov 11, 2021
StartActual
Nov 9, 2021
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 17, 2023
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05117554
Responsible party
Sponsor
First posted
Nov 11, 2021
Start date
Nov 9, 2021
Primary completion
Feb 17, 2023
Completion
Feb 17, 2023
Last update
Oct 17, 2024

Study contacts

Medical Director
study director · Arcus Biosciences, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casdatifan

Start the discussion